Repligen Corp. raised $12.5 million through a private placement and will use the funds in part for its Phase III product, secretin, also called RG1068. (BioWorld Today)

Repligen Corp. raised $12.5 million through a private placement and will use the funds in part for its Phase III product, secretin, also called RG1068. (BioWorld Today)